Husband of 32‑Year‑Old Breast Cancer Victim Urges NHS to Provide Life‑Extending Drug

When Fionnuala Quinlan‑Bennett’s battle with breast cancer ended in June, she was only 32. The young mother from Crawley, West Sussex, had already watched the disease spread to her bones and liver, and she died knowing there was a treatment out there that might have bought her a little more time.

Her husband, Nathan Bennett, describes the anguish of that knowledge in a raw, painfully honest way. “She told me, ‘It’s painful knowing this drug exists and I can’t get it,’” he said, his voice still shaking when he recalls her exact words. The drug in question is Enhertu, a combination of a targeted monoclonal‑antibody therapy and the chemotherapy agent deruxtecan. It is already approved in Scotland and a handful of other countries, but English patients currently can’t access it through the NHS.

For the Bennetts, it isn’t just a medical issue; it’s a matter of fairness. “If you want to honour my memory, go out into the world with a smile and make a difference,” Fionnuala asked friends and family before she passed. She wanted life to continue, not for herself alone but for the children she hoped to teach, the countries she hoped to explore, the books she hoped to read.

Breast Cancer Now, the UK charity that supports patients like Fionnuala, says roughly 1,000 women in England could benefit from Enhertu if it were made widely available. Holly Heath, head of policy and evidence at the charity, urged policymakers to act with urgency: “These women don’t have time to wait. We need a deal now.”

The National Institute for Health and Care Excellence (NICE) had previously ruled the drug not cost‑effective at its listed price, concluding that the benefit didn’t justify the expense. However, after the US‑UK trade agreement was signed in December 2025, NICE announced a new, higher threshold for cost‑effectiveness decisions. The institute said it is now back in talks with the drug’s manufacturer and NHS England to see whether a commercial agreement can be struck.

It’s a complicated dance of economics, politics, and human lives. Yet, for Nathan Bennett and families like his, the calculus is stark: a few more months, maybe years, of precious time versus the cold reality of an unanswered need. “I keep thinking about the what‑ifs,” Nathan confides, “and I can’t stand the idea that another woman might go through the same pain, knowing there’s a medicine just out of reach.”

While the NHS wrestles with budget constraints, the story of Fionnuala’s short, fierce life has become a rallying point for advocates across the country. Social media feeds are filled with tributes, calls to action, and even petitions demanding that Enhertu be added to the list of approved treatments for English patients.

Whether the negotiations will end in a breakthrough remains to be seen. What is clear, however, is that the conversation has been forced into the public arena, and that conversation now includes a husband’s heartbreak, a charity’s determination, and a policy body that is finally re‑examining its earlier decision.

For now, the Bennett family asks only that Fionnuala’s wish be respected: to live fully, to love fully, and to leave a world that helps others do the same.